Literature DB >> 29356568

Usability study and pilot validation of a computer-based emotion recognition test for older adults with Alzheimer's disease and amnestic mild cognitive impairment.

J Antonio García-Casal1,2, Fernando Martínez-Abad3, Teresa Cid-Bartolomé4, Sarah Jane Smith5, Katia Llano-Ordóñez6, M Victoria Perea-Bartolomé2, Miguel Goñi-Imizcoz7, Felipe Soto-Pérez8, Manuel Franco-Martín9.   

Abstract

OBJECTIVES: This study aimed to carry out a pilot validation of Affect-GRADIOR, a computer-based emotion recognition test, with older adults. The study evaluated its usability, reliability and validity for the screening of people with Alzheimer´s disease (AD) and amnestic mild cognitive impairment (aMCI).
METHODS: The test was administered to 212 participants (76.37 ± 6.20 years) classified into three groups (healthy controls, n = 69; AD, n = 84; and aMCI, n = 59) on the basis of detailed neurological, neuropsychological, laboratory and neuro-imaging evidence. Data on usability were collected by means of a questionnaire and automated evaluation.
RESULTS: The validated test comprised 53 stimuli and 7 practice items (one per emotion). Participants reported that Affect-GRADIOR was accessible and user-friendly. It had high internal consistency (ordinal Cronbach's α = 0.96). Test-retest reliability correlations were significant and robust (r = 0.840, p < 0.001). Exploratory factor analysis supported a seven-factor model of the emotions assessed (neutral expression, happiness, surprise, disgust, sadness, anger and fear). Receiver operating characteristic curve analyses suggested that the test discriminated healthy older adults from AD and aMCI cases. Correct answer score improved MMSE predictive power from 0.547 to 0.560 (Cox & Snell R2, p = 0.012), and Affect-GRADIOR speed of processing score improved MMSE predictive power from 0.547 to 0.563 (Cox & Snell R2, p = 0.010).
CONCLUSIONS: Affect-GRADIOR is a valid instrument for the assessment of the facial recognition of emotions in older adults with and without cognitive impairment.

Entities:  

Keywords:  Alzheimer disease; Emotion; affect; mild cognitive impairment; neuropsychology

Mesh:

Year:  2018        PMID: 29356568     DOI: 10.1080/13607863.2017.1423033

Source DB:  PubMed          Journal:  Aging Ment Health        ISSN: 1360-7863            Impact factor:   3.658


  6 in total

1.  Exploring the Relationship Between Deficits in Social Cognition and Neurodegenerative Dementia: A Systematic Review.

Authors:  Esther Setién-Suero; Nancy Murillo-García; Manuel Sevilla-Ramos; Georgelina Abreu-Fernández; Ana Pozueta; Rosa Ayesa-Arriola
Journal:  Front Aging Neurosci       Date:  2022-04-27       Impact factor: 5.702

Review 2.  A Survey of Alzheimer's Disease Early Diagnosis Methods for Cognitive Assessment.

Authors:  Juan Manuel Fernández Montenegro; Barbara Villarini; Anastassia Angelopoulou; Epaminondas Kapetanios; Jose Garcia-Rodriguez; Vasileios Argyriou
Journal:  Sensors (Basel)       Date:  2020-12-18       Impact factor: 3.576

3.  Realization of Self-Adaptive Higher Teaching Management Based Upon Expression and Speech Multimodal Emotion Recognition.

Authors:  Huihui Zhou; Zheng Liu
Journal:  Front Psychol       Date:  2022-03-28

Review 4.  Digital Cognitive Biomarker for Mild Cognitive Impairments and Dementia: A Systematic Review.

Authors:  Zihan Ding; Tsz-Lok Lee; Agnes S Chan
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

5.  COVID-19 in Spain. Coming back to the "new normality" after 2 months of confinement.

Authors:  Raimundo Mateos; Melchor Fernández; Manuel Franco; Manuel Sánchez
Journal:  Int Psychogeriatr       Date:  2020-06-10       Impact factor: 3.878

6.  Computer-based cognitive rehabilitation program GRADIOR for mild dementia and mild cognitive impairment: new features.

Authors:  Manuel A Franco-Martín; Angie A Diaz-Baquero; Yolanda Bueno-Aguado; María T Cid-Bartolomé; Esther Parra Vidales; María V Perea Bartolomé; Isabel de la Torre Díez; Henriëtte G van der Roest
Journal:  BMC Med Inform Decis Mak       Date:  2020-10-22       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.